HOOKIPA Pharma Inc.

NasdaqCM:HOOK Stock Report

Market Cap: US$77.4m

HOOKIPA Pharma Future Growth

Future criteria checks 2/6

HOOKIPA Pharma's earnings are forecast to decline at 8.4% per annum while its annual revenue is expected to grow at 25.8% per year. EPS is expected to grow by 2.9% per annum.

Key information

-8.4%

Earnings growth rate

2.9%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate25.8%
Future return on equityn/a
Analyst coverage

Low

Last updated05 Jun 2024

Recent future growth updates

Recent updates

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18
Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

Hookipa: Speculative Biotech With Key Catalysts In 2022

Mar 29

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Oct 01
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Checking Back In On HOOKIPA Pharma

Jun 22

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers

Jun 08

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Apr 19
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Mar 15
If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Earnings and Revenue Growth Forecasts

NasdaqCM:HOOK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266-131N/AN/A3
12/31/202510-104N/AN/A4
12/31/202454-48N/AN/A4
3/31/202454-48-83-79N/A
12/31/202320-82-62-58N/A
9/30/202321-69-37-33N/A
6/30/202316-68-28-26N/A
3/31/202316-67-28-25N/A
12/31/202214-65-25-20N/A
9/30/202210-74-56-46N/A
6/30/202212-76-59-48N/A
3/31/202215-76-64-50N/A
12/31/202118-76-79-66N/A
9/30/202120-67-72-64N/A
6/30/202120-60-63-57N/A
3/31/202121-50-49-47N/A
12/31/202020-44-42-39N/A
9/30/202018-42-40-37N/A
6/30/202016-40-39-36N/A
3/31/202013-45-39-37N/A
12/31/201912-43-44-42N/A
9/30/201913-35-41-39N/A
6/30/201913-27-38-37N/A
3/31/201910-21-24-22N/A
12/31/20188-16-17-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HOOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HOOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HOOK's revenue (25.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: HOOK's revenue (25.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HOOK's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.